Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncolytics Biotech Inc. -- Ignore unavailable to you. Want to Upgrade?

To: blue_chip who wrote (19)	9/1/2000 12:08:20 PM
From: Gulo	Read Replies (1) \| Respond to of 103

And a longer version: CALGARY, Alberta--(BUSINESS WIRE)--Sept. 1, 2000--Oncolytics Biotech Inc.(TSE:ONC.) reported today that the U.S. Patent and Trademark Office has issued Patent 6,110,461 to the Company effective August 29, 2000. The patent covers the pharmaceutical use of the reovirus in the treatment of Ras-mediated cancers in mammals. "The issuance of this patent provides us with our initial proprietary position with respect to the development of reovirus as a therapeutic for the treatment of cancer," said Dr. Matt Coffey, Vice President Product Development. "It is exciting and gratifying to receive approval for these broad-based claims. It solidifies our platform by providing intellectual property protection and removes an important element of risk in the development and commercialization process". Oncolytics is a Calgary-based biotechnology company whose focus is the development of the reovirus known as REOLYSIN(R) as a potential cancer therapeutic. The human reovirus infects and kills cancer cells with an activated Ras pathway. Ras is an important component of a pathway controlling normal growth and differentiation of a cell, and when activated, may account for a large proportion of all human tumors. Researchers believe that targeting this pathway could have broad potential in the treatment of many cancers. Oncolytics <26>researchers demonstrated that reovirus was selectively able to kill researchers demonstrated that reovirus was selectively able to kill cancer cells with this particular activation and successfully demonstrated that the virus could kill human cancer cells in vitro derived from breast, prostate, pancreatic and brain tumors, as well as being able to treat tumors successfully in a number of animal models. Oncolytics initiated its Phase I clinical trial on REOLYSIN(R) in June 2000. This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements. --30--se/in* CONTACT: Oncolytics Biotech Inc. Dr. Matt Coffey, 403/283-0711 Fax: 403/ 283-0858 E-mail: mattonc@aol.com Website: www.oncolyticsbiotech.com <48> or or Opsis Financial Mr. David Wolk, 416/368-8998 Fax: 416/368-8669 E-mail: dwolk@opsis.ca KEYWORD: CANADA INDUSTRY KEYWORD: MEDICAL BIOTECHNOLOGY Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com